Authors

Moran Shapira, B.Med.Sc., Hila Raanani, M.D., Baruch Feldman, M.D., Ph.D., Naama Srebnik, M.D., Sanaz Dereck-Haim, B.Sc., Daphna Manela, R.N.B.A., Masha Brenghausen, Ph.D., Liat Geva-Lerner, M.D., Ph.D., Eitan Friedman, M.D., Efrat Levi-Lahad, Doron Goldberg, M.D., Tamar Perri, M.D., Talia Eldar-Geva, M.D., Ph.D., Dror Meirow, M.D.

Volume 104, Issue 5, Pages 1162-1167

Abstract

Objective:

To evaluate the association between carriage of BRCA1/2 mutations and ovarian performance, as demonstrated by in vitro fertilization (IVF) outcomes.

Design:

Retrospective cohort study.

Setting:

Two tertiary IVF centers.

Patient(s):

BRCA mutation carriers undergoing IVF for preimplantation genetic diagnosis (PGD) or fertility preservation were compared with non-BRCA PGD or fertility preservation patients, matched by age, IVF protocol, IVF center, and cancer disease status.

Intervention(s):

In vitro fertilization cycles for PGD and fertility preservation.

Main Outcome Measure(s):

Outcome of IVF: oocyte yield, poor response rate, number of zygotes, pregnancy rates.

Result(s):

A total of 62 BRCA mutation carriers and 62 matched noncarriers were included; 42 were fertility preservation breast cancer patients, and 82 were PGD non-cancer patients. Mean (±SD) age of patients was 32 ± 3.58 years. Number of stimulation days and total stimulation dose were comparable between carriers and noncarriers. Their cycles resulted in comparable oocyte yield (13.75 vs. 14.75) and low response rates (8.06% vs. 6.45%). Number of zygotes, fertilization rates, and conception rates were also comparable.

Conclusion(s):

Both healthy and cancer-affected BRCA mutation carriers demonstrated normal ovarian response in IVF cycles.

Read the full text at: http://www.fertstert.org/article/S0015-0282(15)01674-X/fulltext